Abstract
Ulcerative colitis (UC) is a chronic nonspecific intestinal inflammatory disease, which belongs to a subtype of inflammatory bowel disease, but still lacks effective drug treatment. Bletilla striata (B. striata) is one of the most valuable traditional Chinese medicines (TCMs) in China, can stop bleeding, can promote wound healing, and can regulate immunity. Based on data mining, B. striata was found to be a common TCM for the treatment of UC, but the exact therapeutic mechanism is not yet known. This study aims to explore the potential mechanisms of B. striata in the treatment of UC using network pharmacology, molecular docking techniques, and in vivo experimental research. We extracted the active ingredients and targets of B. striata from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and analysis platform. We retrieved and screened the corresponding UC-related target genes in multiple databases. Subsequently, we constructed an herb-ingredient-target-disease-network, generated a protein–protein interaction network, performed Gene Ontology enrichment analysis, and performed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to identify potential treatment mechanisms. After screening for key active ingredients and target genes, we performed molecular docking using AutoDock Vina software to select the best binding target for molecular docking and validate the binding activity. The UC model was established in mice, and the results of network pharmacology and molecular docking were verified by in vivo experiments. In all, 5 compounds were obtained from the TCMSP database, and 74 UC-related pathogenic genes were obtained from GeneCards, DisGeNET, OMIM, TTD, and DrugBank. After KEGG enrichment analysis, pathways in cancer, the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway, and metabolic pathways were identified as the top three signalling pathways associated with UC treatment. The results of molecular docking showed that the active components of B. striata have good binding activities to the pivotal targets epidermal growth factor receptor (EGFR) and PIK3CA. In a dextran sulphate sodium–induced colitis model, we found that B. striata can alleviate the symptoms of UC, decrease the secretion of the inflammatory cytokines interleukin-6 and tumour necrosis factor-α, and downregulate the expression levels of EGFR, PIK3CA, and p-AKT. In conclusion, the treatment of UC with B. striata may alleviate the inflammatory response of the colon, and B. striata mainly inhibits the EGFR/PI3K/AKT signalling pathways.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Ulcerative colitis (UC) is a chronic nonspecific intestinal inflammatory disease of unknown aetiology and a subtype of inflammatory bowel disease (IBD). UC has a long disease course, serious complications, and a high recurrence rate. This condition can lead to toxic megacolon, intestinal perforation, intestinal bleeding, and cancer, which seriously affect the quality of life of patients (Kaplan 2015). The existing epidemiological data in China show that both the incidence and prevalence of IBD have been increasing. According to the statistics of the Chinese Center for Disease Control and Prevention in 2014, the total number of IBD cases in China from 2005 to 2014 was approximately 350,000. The number of IBD patients in China is expected to reach 1.5 million by 2025, with a younger age of onset (Kobayashi et al. 2020).
The aetiology of UC is unknown, and its pathogenesis may be related to the imbalance of intestinal immunity caused by the interaction of multiple factors, such as the environment, genetics, and intestinal microecology (Ungaro et al. 2017). Corticosteroids, 5-aminosalicylic acids, immunomodulators, Janus kinase inhibitors, and biologic agents targeting tumour necrosis factor-alpha (TNF-α), α4β7-integrin, and interleukin (IL)-12/23 have been widely applied in the clinical treatment of UC (Hernandez et al. 2020). However, an increasing number of patients eventually become refractory or intolerant to the side effects or complications of drugs, and some even require colectomy. In addition, the risk of colorectal cancer in UC is significantly increased due to the continuous infiltration of immune cells and repeated stimulation of the intestinal mucosal epithelium (Pike and Tremblay 2018). Traditional Chinese medicine (TCM) is regarded as a form of “complementary and alternative medicine” in the Chinese healthcare system and provides new options for standard therapy. Bletilla striata (B. striata) is one of the most valuable TCMs in China, was first recorded in the Shennong Herbal Scripture, and has a history of more than 2000 years (Chen et al. 2018). This herb has effects on haemostasis, detumescence, muscle generation, and sore convergence (Xu et al. 2019). Modern pharmacology has found that B. striata can stop bleeding, promote wound healing, and regulate immunity (Jiang et al. 2019a, b). Based on data mining, B. striata was found to be a common drug for the treatment of UC (Jia et al. 2021). Many clinical trials have also confirmed that B. striata can protect the intestinal mucosa, promote the healing of intestinal ulcers, and improve the symptoms of intestinal inflammation and blood in the stool (Zheng et al. 2010; Xu et al. 2014), but its mechanism of action is still unclear.
Network pharmacology combines pharmacology, bioinformatics, and other scientific and systematic network analyses to study the pharmacological mechanism of TCM. Its integrity and systematic characteristics are consistent with the overall concept of TCM and the principle of syndrome differentiation and treatment, which has been widely used in TCM research. In this study, a network pharmacology approach was used for the first time to screen the effective bioactive components and targets of B. striata and to analyse its key targets and signalling pathways for the treatment of UC, guiding further research of this formula. The detailed workflow of this study is shown in Fig. 1.
Materials and methods
Network pharmacology
B. striata ingredient collection and target gene prediction
Screening of active ingredients of B. striata was performed using the TCM Systems Pharmacology (TCMSP) database and analysis platform (https://tcmspw.com/tcmsp.php) (Ru et al. 2014). Then, we used pharmacokinetic information retrieval filters for absorption, distribution, metabolism, and excretion screening based on oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18. Target genes were predicted using the TCMSP database after identifying the active ingredients. Predictive target gene names were standardized from the UniProt database (https://www.uniprot.org/) (UniProt. 2019). Cytoscape software was used to draw the composition and target gene network of B. striata.
Prediction of UC-related pathogenic genes
GeneCards (https://www.genecards.org/) (Safran et al. 2010), DisGeNET (https://www.disgenet.org/) (Piñero et al. 2019), OMIM (http://www.omim.org/) (Amberger et al. 2020), TTD (https://idrblab.org/ttd/) (Wang et al. 2020), and DrugBank (https://www.drugbank.ca/) (Wishart et al. 2018) were selected to obtain UC-related pathogenic genes. All the databases used “ulcerative colitis” as the keyword.
Protein–protein interaction (PPI) network and topological analysis
To clarify the interaction between the predicted target of the main active components of B. striata and the target of UC, we investigated the intersection of the above target genes. Then, the common target genes were uploaded to the Search Tool for the Retrieval of Interacting Genes (STRING) database (http://string-db.org/) (Szklarczyk et al. 2021). Furthermore, the condition was restricted to “Homo sapiens,” and the free points were hidden. In this study, a medium confidence score above 0.4 was selected to obtain PPI data. Next, the interaction files were downloaded and imported into Cytoscape to visualize the PPI network and analyse the topological value. Furthermore, the topology parameter of the degree value was determined by the “NetworkAnalyzer”, an analytical tool in Cytoscape 3.9.0. The top 10 ranked proteins were defined as hub targets based on the degree level.
Enrichment analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)
The biological process (BP), molecular function (MF), and cell component (CC) enrichment analyses were carried out using the Metascape system (https://metascape.org/) (Zhou et al. 2019), in which the background as an organism was selected as “Homo sapiens” for customized analysis with a cut-off P value of < 0.05. The KEGG database (https://www.kegg.jp/kegg/) (Kanehisa et al. 2021) was applied for KEGG enrichment analysis.
Component-target molecular docking
Molecular docking is a method of placing the ligand in the binding area of the receptor through computer simulation and calculating its physical and chemical parameters to predict the binding affinity and conformation of the ligand and receptor. Receptor and ligand files were downloaded from the PubChem (https://pubchem.ncbi.nlm.nih.gov/) and PDB (https://www.rcsb.org) databases. AutoDock Vina software (Eberhardt et al. 2021) was used for molecular docking.
Animal experimental study
Dose and preparation of B. striata decoction
According to the 2020 edition of the Pharmacopoeia of the People’s Republic of China (National Pharmacopoeia Committee 2020), the maximum dosage of B. striata for human adults is 15 g per day. The raw material was purchased from The Third Affiliated Hospital of Zhejiang Chinese Medical University. The raw material was soaked in 8 times the volume of distilled water for 1 h, then boiled for 20 min, and decocted 2 times. The two decoctions were mixed and filtered with gauze and centrifuge. Finally, the filtrate is concentrated by rotary evaporation to 100% of the solution (i.e. 1 g of raw drug per 1 mL of solution) and stored at 4 ℃ for backup.
Animal modelling and drug treatment
Male C57BL/6 mice (8–10 weeks of age) were randomly divided into six groups (n = 10/group): control group, model group, lowdose (1 g/kg•day−1) B. striata decoction group (BSL group), mediumdose (2 g/kg•day−1) B. striata decoction group (BSM group), highdose (4 g/kg•day−1) B. striata decoction group (BSH group), and mesalazine group. Colitis was induced in mice by administering 3% (w/v) dextran sulphate sodium (DSS) in their drinking water for 7 days. On days 8 to 16, the mice were switched to normal water and treated with low, medium, and high doses of B. striata decoction or mesalazine (0.5 g/kg•day−1). The doses of 1 g/kg•day−1, 2 g/kg•day−1, and 4 g/kg•day−1 B. striata decoction are equivalent to 0.5 times, 1.0 times, and 2.0 times the human adult dose, respectively. All animal experiments were performed with the approval of the local ethical committee of Zhejiang Chinese Medical University and conducted in accordance with the relevant guidelines of the Animal Center of Zhejiang Chinese Medical University.
Disease activity index (DAI)
DAI was assessed based on weight loss, diarrhoea, and rectal bleeding. Weight loss was defined as the difference between the initial and final weights. Diarrhoea was defined as the absence of faecal pellet formation and the presence of continuous fluid faecal material in the colon. Rectal bleeding was defined based on the presence of diarrhoea containing visible blood and on the presence of gross rectal bleeding. The DAI value was calculated using the following formula: DAI = [(body weight loss score) + (diarrhoea score) + (haematochezia score)]/3 (Table 1) (Liu et al. 2021).
Histological colitis score
Colon sections were fixed in 10% formalin, embedded in paraffin, and stained with haematoxylin and eosin for histological scoring. Histological colitis score = inflammation + depth of lesions + destruction of crypt + width of lesions (see Table 2 for details (Dieleman et al. 1998)).
Real-time quantitative PCR
One-Step TB Green PrimeScript PLUS Perfect Real-Time (TaKaRa Bio, Shiga, Japan) and ABI 7500 Fast Real-Time PCR (Thermo Fisher Scientific) were used for reverse transcription and amplification of RNA according to the manufacturer’s instructions. The primer sequences are listed in Table 3. The relative expression of target genes was calculated using the 2ΔΔ CT method with β-actin as a normalized control.
Enzyme-linked immunosorbent assay (ELISA)
EGFR, PIK3CA, p-AKT, TNF-α, and IL-6 protein expression levels were measured by mouse EGFR, PIK3CA, p-AKT, TNF-α, and IL-6 ELISA kits (Shanghai Fanke Industrial Co., Ltd., Shanghai, China) according to the manufacturer’s instructions.
Western blot
The protein expression levels of EGFR, PIK3CA, and p-AKT were tested again by Western blot, and the bands were analysed by ImageJ software. The primary antibodies used were as follows: EGFR (#4267: Cell Signaling Technology, Danvers, MA, USA), PIK3CA (#4249: Cell Signaling Technology, Danvers, MA, USA), p-AKT (#9271: Cell Signaling Technology, Danvers, MA, USA), and GAPDH (#5174: Santa Cruz Biotechnology, CA, USA). Secondary antibodies used were goat anti-rabbit IgG-HRP (#SC-2004, Santa Cruz Biotechnology, Dallas, TX, USA).
Statistical analysis
All graphs and statistical analyses were prepared and performed using GraphPad Prism version 9.0.0 (GraphPad Software, La Jolla, CA, USA). One-way analysis of variance (ANOVA) was used for comparisons between groups, followed by Bonferroni post hoc tests for multiple comparisons; otherwise, the Tamhane T2 method was used. All data are expressed as the mean ± SD. P < 0.05 was considered statistically significant.
Results
Screening of active ingredients and target genes of B. striata
In the TCMSP database, B. striata contains 36 active ingredients in total. These components were then screened with OB ≥ 30% and DL ≥ 0.18 as the conditions. Consequently, 9 active ingredients were obtained. However, 4 active ingredients of B. striata, 2,7-dihydroxy-4-methoxyphenanthrene-2,7-O-diglucoside (MOL005759), 3,7-dihydroxy-2,4-dimethoxyphenanthrene-3-O-glucoside (MOL005766), bletlol A (MOL005770), and blespirol (MOL005773), were eliminated because they could not be found in PubChem (https://pubchem.ncbi.nlm.nih.gov/). Therefore, a total of 5 active ingredients were included in the next step of the study (Table 4) (Supplementary file 1).
In addition, we collected targets of potential active ingredients in B. striata using the TCMSP database and annotated the target genes using UniProt data. There were 410 corresponding targets of B. striata. After removal of duplicate targets, a total of 216 human-derived target proteins were obtained. The active compound-target network of B. striata is shown in Fig. 2 (Supplementary file 1).
Common targets of B. striata and UC
To confirm the therapeutic effect of B. striata on UC, we collected 2047 different target genes of UC and 216 target genes of B. striata from various databases. Through their crossover, we obtained 78 common target genes that are shown in Fig. 3 (Supplementary file 1).
Construction of the PPI network and core target screening
Seventy-eight overlap** genes of B. striata and UC were submitted to the STRING database. Moreover, the free points (HTR7, AKR1B10, CACNA2D1, and BDKRB2) were hidden. Finally, 74 target genes with moderate connectivity (degree ≥ 0.400) in the PPI network were obtained (Fig. 4). The tsv file was downloaded in STRING, and the PPI network was analysed with Cytoscape v3.9.0. According to the degree values, the top 10 core targets were identified as EGFR, SRC, ESR1, CCND1, ERBB2, PTGS2, PIK3CA, MMP9, MDM2, and MCL1 (Fig. 5), whose full names are provided in Table 5 (Supplementary file 1).
GO/KEGG analysis
Furthermore, GO and pathway enrichment analyses were performed to explore the biological processes of 74 putative targets of B. striata in UC. As shown in Figs. 6, 7, and 8, the top 10 most significantly enriched GO biological processes, cellular components, and molecular functions were identified with their q-value and gene count. Biological processes were mainly related to the regulation of protein kinase activity, transmembrane receptor protein tyrosine kinase signalling pathway, regulation of protein serine/threonine kinase activity, and peptidyl-tyrosine phosphorylation. The cellular components were mainly related to the transferase complex, protein kinase complex, and cyclin-dependent protein kinase holoenzyme complex. Moreover, the molecular functions were mainly related to protein kinase activity, kinase activity, phosphotransferase activity, and protein tyrosine kinase activity. KEGG pathway enrichment analysis screening resulted in 211 signalling pathways. As Fig. 9 shows, the top 10 signalling pathways of B. striata in the treatment of UC were concentrated in pathways in cancer, the PI3K-Akt signalling pathway, metabolic pathways, microRNAs in cancer, endocrine resistance, proteoglycans in cancer, prostate cancer, human papillomavirus infection, the Rap1 signalling pathway, and chemical carcinogenesis (Supplementary file 1).
Verification with molecular docking
To further validate the results of network pharmacological screening, we linked the five active compounds of B. striata to the hub targets EGFR and PIK3CA by molecular docking. Generally, the Vina score is negative; the lower the score is, the better the binding activity between the ligand and receptor is. As shown in Table 6 and Figs. 10 and 11, except for 2,3,4,7-tetramethoxyphenanthrene, the active components of B. striata have good binding activities to the pivotal targets EGFR and PIK3CA, and the binding activity to EGFR is better than that of PIK3CA (Supplementary file 1).
Results of the animal experimental study
B. striata ameliorated DSS-induced colitis symptoms
To investigate the protective effect of B. striata on UC, we generated a mouse model of DSS-induced colitis. Mesalazine was used as a positive control in this study. As Fig. 12A shows, on the 7th day of modelling, the mice in the control group had shiny hair, normal diet and activity, dry stools, no anal bleeding, and normal weight gain. In contrast, the mice in the BS-L group, BS-M group, BS-H group, and mesalazine group had dull hair, depression, blood in the stool, anal bleeding, and significant weight loss (Fig. 13). However, after 10 days of treatment, all the remaining groups showed relief of symptoms after each dose compared to the model group.
Evaluation of the effectiveness of B. striata on UC based on weight loss, colon length, DAI score, and colon histopathology score was performed. On day 7 of DSS induction, the body weight of the model group decreased significantly compared to that of the control group and decreased daily thereafter. Compared with the treatment in the model group, the administration of medium-dose B. striata decoction, highdose B. striata decoction, and mesalazine significantly alleviated body weight loss (P < 0.001, Fig. 12B). The DAI and colon histopathology scores are shown in Fig. 12C, E, and we found that compared with the control group, the model group had significantly increased values, whereas compared with those in the model group, the DAI and colon tissue histopathology scores in the mesalazine group and B. striata groups were decreased. In addition, the DAI and colon tissue histopathology scores in the B. striata groups decreased with an increase in the dose. DSS resulted in a significant shortening of the colon length. As shown in Fig. 12D, the colon length in the model group was significantly shorter than that in the control group (4.98 ± 0.25 vs. 6.73 ± 0.18, P < 0.001). However, compared with that in the model group, the colon length in the medium-dose and high-dose B. striata decoction, and mesalazine groups was significantly restored (6.58 ± 0.14 vs. 4.98 ± 0.25; 7.53 ± 0.20 vs. 4.98 ± 0.25; 7.43 ± 0.27 vs. 4.98 ± 0.25; P < 0.001) (Supplementary file 2).
B. striata inhibited the proinflammatory cytokines in colon tissues
Proinflammatory factors play a vital role in the pathogenesis and progression of UC. To determine whether B. striata exerts anti-inflammatory effects in DSS-induced colitis, we examined the expression levels of the proinflammatory cytokines TNF-α and IL-6 in colon tissues by ELISAs. We found that DSS significantly triggered the expression of proinflammatory cytokines, including TNF-α (394.01 ± 21.06 vs. 120.06 ± 2.12, P < 0.001) (Fig. 14A) and IL-6 (464.06 ± 38.29 vs. 160.69 ± 10.94, P < 0.001) (Fig. 14B), compared with those in the control group. However, the administration of mediumdose and highdose B. striata decoction, and mesalazine inhibited the content of TNF-α (185.92 ± 20.26 vs. 394.01 ± 21.06; 145.69 ± 12.36 vs. 394.01 ± 21.06; 124.83 ± 5.38 vs. 394.01 ± 21.06; P < 0.001) (Fig. 14A) and IL-6 (206.95 ± 19.81 vs. 464.06 ± 38.29; 162.59 ± 12.35 vs. 464.06 ± 38.29; 177.20 ± 13.04 vs. 464.06 ± 38.29; P < 0.001) (Fig. 14B) significantly compared with that of the model group. These data demonstrated that mediumdose and highdose B. striata decoction, and mesalazine could restrain the proinflammatory reaction in UC (Supplementary file 2).
B. striata ameliorated DSS-induced inflammation through the EGFR/PI3K/AKT signalling pathway
Inflammation plays an important role in the pathogenesis and course of UC, and the inflammatory response may be mediated in part by the EGFR/PI3K/AKT signalling pathway (Liu et al. 2021). Based on network pharmacology analysis and molecular docking technology, we found that the therapeutic effect of B. striata on UC may be related to the EGFR/PI3K/AKT signalling pathway. Therefore, we demonstrated through animal experiments that B. striata could inhibit inflammation in UC by regulating the expression of EGFR, PI3K, and p-AKT. Finally, RT-qPCR, Western blot, and ELISA results showed that the mRNA and protein expression levels of EGFR, PI3K, and p-AKT were markedly increased in the colon tissue of the model group (Fig. 15), which indicated that the EGFR/PI3K/AKT signalling pathway was activated in UC. Noteworthily, the rise of these targets was prevented by B. striata treatment. Combining the above results, we drew the following conclusion: B. striata may treat UC by inhibiting the activation of the EGFR/PI3K/AKT signalling pathway (Supplementary file 2).
Discussion
UC is a chronic nonspecific intestinal inflammatory disease of unknown aetiology, a subtype of IBD, and is refractory and persistent, showing recurrence and the risk of intestinal perforation, toxic megacolon, and cancer, which strongly limit patients’ daily life and work. B. striata, as a classic Chinese herbal medicine, has astringent effects and effects on haemostasis, swelling, and muscle growth. Based on data mining of TCM for the treatment of UC, it was found that B. striata is a common Chinese herbal medicine for the treatment of UC that can protect the intestinal mucosa, promote the healing of intestinal ulcers, and improve intestinal inflammation and symptoms of blood in the stool, but its mechanism of action is unclear. This study analysed the active compounds, potential targets, and relevant pathways of B. striata for the treatment of UC through network pharmacology. Finally, 5 compounds and 74 target genes were identified and were significantly enriched in multiple UC-related pathways, such as the cancer pathway, PI3K-AKT signalling pathway, and metabolic pathways. Furthermore, the molecular docking results showed that the key active compounds in B. striata showed good binding affinity to EGFR and PIK3CA. This study comprehensively clarified the putative active components and multitarget mechanism of B. striata in UC and provided a theoretical basis for the clinical application of B. striata in the treatment of UC.
Among the identified compounds associated with this network, the majority of UC-related chemical components in B. striata are dihydrophenanthrene and phenanthrene compounds, especially 9,10-dihydrophenanthrene. Dihydrophenanthrene and phenanthrene are the main active components of B. striata, and numerous studies have shown that they have significant anti-inflammatory activity (Kovács et al. 2008; Lin et al. 2013; Wang et al. 2017). The anti-inflammatory mechanism of dihydrophenanthrene and phenanthrene may be related to the inhibition of inflammatory factors as well as the PI3K/AKT, NF-κB, and MAPK signalling pathways (Jiang et al. 2019a, b; Lin et al. 2013). In addition, many studies have demonstrated that dihydrophenanthrene and phenanthrene compounds have anticytotoxic activity and have significant curative effects on cancer-related diseases (Wang et al. 2017; He et al. 2017; Sun et al. 2016). This finding indicates that they not only play a role in the treatment of UC but also inhibit the carcinogenesis induced by colon inflammation, thereby controlling the transformation of UC to colon cancer. Interestingly, recent research identified 9,10-dihydrophenanthrene derivatives as potent noncovalent SARS-CoV-2 3CLpro inhibitors for the treatment of COVID-19 (Zhang et al. 2022). Thus, dihydrophenanthrene may also have antiviral effects.
Through network pharmacology, we finally obtained 74 potential target genes for UC, such as EGFR, SRC, ESR1, CCND1, ERBB2, PTGS2, PIK3CA, and other key targets. Through GO enrichment analysis, we discovered that the targets of B. striata for the treatment of UC were associated with various biological processes, such as regulation of protein kinase activity, regulation of protein serine/threonine kinase activity, peptidyl-tyrosine phosphorylation, and peptidyl-tyrosine modification. According to KEGG pathway enrichment analysis, we found that the PI3K-AKT signalling pathway, pathways in cancer, and metabolic pathways were the most important. Moreover, EGFR is a key target for prediction. This molecule initiates the PI3K/AKT signalling pathway, which is closely linked to the regulation of cellular functions such as cell proliferation, differentiation, and apoptosis. During intestinal inflammation in experimental colitis mouse models and the colon of UC patients, colonic EGFR expression is upregulated (Lu et al. 2014). EGFR signalling is also an important marker of colitis-related colorectal carcinogenesis (Ko et al. 2019; Singh et al. 2018). PI3K/AKT is a key downstream signalling pathway of EGFR, and abnormal activation of the PI3K/AKT signalling pathway is associated with the development of UC, as well as promoting colon cancer cell proliferation, prolonging cell survival, inhibiting cell apoptosis, and participating in angiogenesis, leading to invasion and metastasis of colon cancer (Jiang et al. 2019a, b; Zhang et al. 2021). In addition, the PI3K-AKT pathway is closely related to the regulation of the inflammatory response during UC progression. The expression levels of inflammatory factors such as TNF-α, IL-1β, and IL-6 in UC were increased by abnormal activation of the PI3K/AKT signalling pathway (Li et al. 2019a, b; Li et al. 2019a, b). Furthermore, TNF-α is an important proinflammatory cytokine involved in the pathogenesis of UC, inducing the pathological opening of the intestinal tight junction barrier, increasing intestinal epithelial permeability, and disrupting intestinal barrier function (**ang et al. 2021; Shin et al. 2020). Therefore, anti-TNF-α therapy has been widely used in clinical practice as a suitable method of UC treatment. In addition, our molecular docking results confirmed that the active ingredients of B. striata are effectively bound to the hub genes EGFR and PIK3CA. Therefore, we hypothesized that B. striata might have a therapeutic effect on UC by regulating the EGFR/PI3K/Akt signalling pathway to reduce the inflammatory response.
To investigate the effect of B. striata on the inflammatory response and the role of the EGFR-regulated PI3K/AKT signalling pathway in UC, we established a mouse model of colitis. The model group showed more severe damage and acute colitis, and these abnormalities were alleviated by B. striata or mesalazine. In addition, B. striata and mesalazine ameliorated body weight loss, shortening of the colon length, DAI, pathological changes, and secretion of inflammatory cytokines, and there were no significant differences between the BS-M and BS-H groups and the mesalazine group. To verify whether the mechanism by which B. striata treats UC is related to the EGFR/PI3K/AKT signalling pathway, we detected the mRNA expression levels of EGFR and PIK3CA by RT-qPCR and detected the protein expression levels of EGFR, PIK3CA, and p-AKT by Western blot and ELISA. The results indicated that the EGFR/PI3K/AKT signalling pathway is abnormally activated in the DSS-induced colitis model. However, the expression levels of EGFR, PI3K, and p-AKT in colon tissue in the BS-M and BS-H groups were significantly lower than those in the model group. Combined with network pharmacology analysis, molecular docking, and in vivo experiments, the results showed that B. striata can effectively downregulate the expression of EGFR, PI3K, and p-AKT, which may help to improve UC.
Conclusion
In this study, we initially screened 5 active compounds of B. striata. The key targets, including EGFR and PIK3CA, were obtained and verified by molecular docking, and the top EGFR/PI3K/AKT signalling pathway was further analysed. We found that B. striata could inhibit inflammatory cytokines, reduce the inflammatory response to UC, and alleviate the symptoms of UC in mice. Furthermore, B. striata reduced the mRNA expression of EGFR and PIK3CA and the protein expression of EGFR, PIK3CA, and p-AKT. Therefore, we believe that B. striata can affect the EGFR/PI3K/Akt signalling pathway, resulting in an anti-UC effect.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A (2020) OMIM. org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 43(Database issue): D789-D798
Chen BC, Lin CX, Chen NP, Gao CX, Zhao YJ, Qian CD (2018) Phenanthrene antibiotic targets bacterial membranes and kills Staphylococcus aureus with a low propensity for resistance development. Front Microbiol 9:1593
Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, Rees EPV (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385–391
Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings. J Chem Inf Model. 61(8): 3891–3898
He XR, **aoxiao Wang XX, FangJC ZZF, Huang LH, Guo H, Zheng XH (2017) Bletilla striata: medicinal uses, phytochemistry and pharmacological activities. J Ethnopharmacol 195:20–38
Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R (2020) Cost-effectiveness analysis of vedolizumab compared with other biologics in anti-TNF-naive patients with moderate-to-severe ulcerative colitis in Japan. 38(1): 69-84
Jia Y, Wang ZZ, Li XM, Miao MS (2021) Data mining of drug use rules based on traditional Chinese medicine treatment of ulcerative colitis. Zhongguo Zhong Yao Za Zhi 46(10):2594–2600
Jiang FS, Li MY, Wang HY, Ding B, Zhang CC, Ding ZS, Yu XB, Lv GY (2019a) Coelonin, an anti-inflammation active component of Bletilla striata and its potential mechanism. Int J Mol Sci 20(18):4422
Jiang W, Han YP, Hu M, Bao XQ, Yan Y, Chen G (2019b) A study on regulatory mechanism of miR-223 in ulcerative colitis through PI3K/AktmTOR signaling pathway. Eur Rev Med Pharmacol Sci 23(11):4865–4872
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M (2021) KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 49(D1):D545–D551
Kaplan GG (2015) The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 12(12):720–727
Ko YS, Bae JA, Kim KY, Kim SJ, Sun EG, Lee KH, Kim N, Kang H, Seo YW, Kim H et al (2019) MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis. Oncogene 38(49):7416–7432
Kobayashi T, Siegmund B, Berre CL, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T (2020) Ulcerative Colitis. Nat Rev Dis Primers 6(1):74
Kovács A, Vasas A, Hohmann J (2008) Natural phenanthrenes and their biological activity. Phytochemistry 69(5):1084–1110
Li MY, Luo HJ, Wu X, Liu YH, Gan YX, Xu N, Zhang YM, Zhang SH, Zhou CL, Su ZR et al (2019a) Anti-inflammatory effects of Huangqin decoction on dextran sulfate sodium-induced ulcerative colitis in mice through regulation of the gut microbiota and suppression of the Ras-PI3K-Akt-HIF-1α and NF-κB pathways. Front Pharmacol 10:1552
Li N, Sun WJ, Zhou X, Gong H, Chen YQ, Chen DF, **ang F (2019b) Dihydroartemisinin protects against dextran sulfate sodium-induced colitis in mice through inhibiting the PI3K/AKT and NF-κB signaling pathways. Biomed Res Int 2019:1415809
Lin Y, Wang F, Yang LJ, Chun Z, Bao JK, Zhang GL (2013) Anti-inflammatory phenanthrene derivatives from stems of Dendrobium denneanum. Phytochemistry 95:242–251
Liu XL, Fan YL, Du LP, Mei ZG, Fu Y (2021) In silico and in vivo studies on the mechanisms of Chinese medicine formula (Gegen Qinlian decoction) in the treatment of ulcerative colitis. Front Pharmacol 12:665102
Lu N, Wang LH, Cao HL, Liu LP, Kaer LV, Washington MK, Rosen MJ, Dubé PE, Wilson KT, Ren XB et al (2014) Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. J Immunol 192(3):1013–1023
National Pharmacopoeia Committee (2020) Pharmacopoeia of the People’s Republic of China 2020 edition. Bei**g: China Medical Science and Technology Press
Pike KA, Tremblay ML (2018) Protein tyrosine phosphatases: regulators of CD4 T cells in inflammatory bowel disease. Front Immunol 9:2504
Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, Furlong FI (2019) The DisGeNET knowledge platform for disease genomics update. Nucleic Acids Res 48(D1):D845–D855
Ru JL, Li P, Wang JN, Zhou W, Li BH, Huang C, Li PD, Guo ZH, Tao WY, Yang YF et al (2014) TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 6(1):13
Safran M, Dalah I, Alexander J, Rosen N, Stein TI, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H et al (2010) GeneCards version 3: the human gene integrator. Database (Oxford). 2010: baq020
Shin J, Song HY, Lee M (2020) Sudachinoid- and ichangensin-type limonoids from Citrus junos downregulate pro-inflammatory cytokines. Int J Mol Sci 21(18):6963
Singh K, Coburn LA, Asim M, Barry DP, Allaman MM, Shi CJ, Washington MK, Luis PB, Schneider C, Delgado AG et al (2018) Ornithine decarboxylase in macrophages exacerbates colitis and promotes colitis-associated colon carcinogenesis by impairing M1 immune responses. Cancer Res 78(15):4303–4315
Sun AJ, Liu JQ, Pang SQ, Lin JS, Xu RA (2016) Two novel phenanthraquinones with anti-cancer activity isolated from Bletilla striata. Bioorg Med Chem Lett 26(9):2375–2379
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P et al (2021) The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 49(D1):D605–D612
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombelet JF (2017) Ulcerative colitis. Lancet 389(10080):1756–1770
UniProt C (2019) UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 47(D1):D506–D515
Wang C, Luo WF, Li PW, Li SD, Yang ZM, Hu Z, Liu YY, Ao NJ (2017) Preparation and evaluation of chitosan/alginate porous microspheres/Bletilla striata polysaccharide composite hemostatic sponges. Carbohydr Polym 174:432–442
Wang YX, Zhang S, Li FC, Zhou Y, Zhang Y, Wang ZW, Zhang RY, Zhu J, Ren YX, Tan Y et al (2020) Therapeutic target database: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res 48(D1):D1031–D1041
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z et al (2018) DrugBank 5.0: a major update to the DrugBank database. Nucleic Acids Res. 46(D1): D1074-D1082
**ang XW, Jiang QH, Shao W, Li JH, Zhou YF, Chen L, Deng SG, Zheng B, Chen YF (2021) Protective effects of shrimp peptide on dextran sulfate sodium-induced colitis in mice. Front Nutr 8:773064
Xu DL, Pan YC, Chen JS (2019) Chemical constituents, pharmacologic properties, and clinical applications of Bletilla striata. Front Pharmacol 10:1168
Xu JY, Chang XW, Ding RF, Zhang MJ (2014) Influence of Baiji Yuyang decoction on immune function in elderly patients with ulcerative colitis. Chin J Gerontol 34(8):2121–2122 (Chinese)
Zhang HY, Sun JA, Ma RT, Zhao SJ (2021) Role of episamarcandin in promoting the apoptosis of human colon cancer HCT116 cells through the PI3K-Akt signaling pathway. Evid Based Complement Alternat Med 2021:9663738
Zhang JW, **ong Y, Wang F, Zhang FM, Yang XD, Lin GQ, Tian P, Ge GB, Gao DD (2022) Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL pro inhibitors for treating COVID-19. Eur J Med Chem 228:114030
Zheng ZC, Shen H, Zhu XX, Liu Y (2010) Effects of Cortex Philodendra, Radix Sanguisorbae and Rhizoma Bletillae on the expression of cytokines and NF-кB in ulcerative colitis rats. JETCM 19(3):469–472 (Chinese)
Zhou YY, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK (2019) Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10(1):1523
Funding
This study was supported by the National Natural Science Foundation of China (grant number 81473506); Zhejiang TCM Science and Technology Project (grant number 2023ZL464); and Hospital-Level Project of the Third Affiliated Hospital of Zhejiang Chinese Medical University (grant number YJKY-2020–10-01).
Author information
Authors and Affiliations
Contributions
G-SS performed the experiments, analysed the data, and wrote the paper. L-RH performed parts of the experiments and provided valuable suggestions for this study. Z-MQ and F-YH designed the research and revised the paper. S-YC completed the statistical analysis in the article. The authors declare that all data were generated in-house and that no paper mill was used.
Corresponding author
Ethics declarations
Ethics approval
The ethical code of this project is IACUC-20210830–12.
Consent to participate
This is an animal study.
Consent for publication
All authors agree to publish.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gong, S., Lv, R., Fan, Y. et al. The potential mechanism of Bletilla striata in the treatment of ulcerative colitis determined through network pharmacology, molecular docking, and in vivo experimental verification. Naunyn-Schmiedeberg's Arch Pharmacol 396, 983–1000 (2023). https://doi.org/10.1007/s00210-022-02370-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-022-02370-9